Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surrozen, Inc. (SRZNW for its warrants and SRZN for its common stock) files reports and disclosure documents with the U.S. Securities and Exchange Commission as a public biotechnology company in the biological product manufacturing industry. This SEC filings page brings together those documents so users can review how Surrozen describes its business, capital structure, and material events in official regulatory submissions.
Surrozen’s filings include Form 8-K current reports that outline significant corporate developments. For example, one Form 8-K describes a Sales Agreement with TD Securities (USA) LLC (TD Cowen) that allows Surrozen to offer and sell shares of its common stock in at-the-market offerings under a Form S-3 registration statement. The filing explains that TD Cowen may sell shares on the Nasdaq Capital Market or other existing trading markets, and that Surrozen will pay a commission on gross sales proceeds and provide customary indemnification.
Another Form 8-K details the issuance of a press release announcing Surrozen’s financial results for a specific quarter, categorized under "Results of Operations and Financial Condition." In that report, the company notes that the information, including the press release exhibit, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Such filings help readers understand how Surrozen reports its operating performance and significant events.
On this page, users can access Surrozen’s SEC filings as they are made available through EDGAR, including current reports like Form 8-K, registration statements such as Form S-3, and related exhibits. AI-powered summaries can assist in interpreting key sections, such as descriptions of capital-raising arrangements, warrant and common stock references, and other disclosures about Surrozen’s Wnt pathway-focused biotechnology business.
Surrozen, Inc. reported that board member Shao-Lee Lin, M.D., Ph.D. resigned from its Board of Directors, effective immediately on January 26, 2026. The company stated that Dr. Lin’s resignation was not due to any disagreement regarding Surrozen’s operations, policies, or practices. Surrozen expressed appreciation for her service and dedication to the company’s mission.
Surrozen, Inc. (SRZN) received an initial ownership report showing that investment entities affiliated with TCG Crossover hold significant stakes in its common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., together with their general partners, each report indirect beneficial ownership of 637,005 shares of Surrozen common stock as of 01/26/2026. The funds hold the shares of record, while their general partners and Chen Yu, as sole managing member of each general partner, may be deemed to share voting, investment, and dispositive power over the reported securities.
Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received an employee stock option grant. On 01/23/2026, he was awarded options to purchase 500 shares of Surrozen common stock at an exercise price of $19.595 per share. These options expire on 01/22/2036 if not exercised.
The 500 options vest over four years in 48 equal monthly installments starting from the grant date, and are held directly by the executive. After this grant, he beneficially owns 500 derivative securities linked to Surrozen common stock.
Surrozen, Inc. received an amended Schedule 13D from venture capital firm The Column Group and related entities detailing their ownership of the company’s common stock. The filing shows that funds affiliated with The Column Group, together with managing partners Tim Kutzkey and Peter Svennilson, beneficially own 3,824,612 shares, or 35.1% of Surrozen’s common stock based on 10,885,617 shares outstanding.
The Column Group III GP, LP is reported as beneficially owning 2,962,544 shares, representing 28.6% of the class, while The Column Group III, LP and The Column Group III-A, LP report stakes of 14.2% and 15.9%, respectively. The Column Group Opportunity III–branded entities each report beneficial ownership of 862,068 shares, or 8.8% of the class.
The amendment also records a series of open-market purchases by TCG III LP and TCG III-A LP between November 13, 2025 and January 20, 2026 at prices ranging from
Surrozen, Inc. (SRZN) reported insider buying by investment funds affiliated with The Column Group. Multiple Column Group limited partnerships, each a 10% owner, disclosed open‑market purchases of Surrozen common stock on January 15, 16 and 20, 2026.
Examples include The Column Group III, LP buying 5,590 shares at $19.889 and 8,484 shares at $19.5999, and The Column Group III-A, LP buying 6,303 shares at $19.889 and 9,568 shares at $19.5999. Following these purchases, The Column Group III, LP reported beneficial ownership of 900,292 shares, The Column Group III-A, LP reported 1,016,658 shares, and The Column Group Opportunity III, LP reported holding 344,827 shares.
The filing notes that general partners and managing partners associated with these funds may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.
Surrozen, Inc. director and 10% owner Tim Kutzkey reported indirect open‑market purchases of the company’s common stock by investment funds he helps manage. Between January 15 and January 20, 2026, The Column Group III, LP and The Column Group III-A, LP bought a total of 32,507 shares at prices around $19.60–$20.00 per share. After these transactions, The Column Group III, LP held 900,292 shares, The Column Group III-A, LP held 1,016,658 shares, and The Column Group Opportunity III, LP held 344,827 shares, all reported as indirectly beneficially owned. The general partners and managing partners, including Kutzkey, disclaim beneficial ownership except to the extent of their pecuniary interest.
Surrozen, Inc. entered into a Sales Agreement with TD Securities (USA) LLC (referred to as TD Cowen) that allows the company to sell, from time to time, up to $50.0 million of its common stock through an at-the-market offering. TD Cowen will act as sales agent and/or principal and use commercially reasonable efforts to execute sales based on Surrozen’s instructions, including price, timing, and size parameters. Surrozen will pay TD Cowen a commission of up to 3.0% of the gross sales proceeds for any shares sold, and either party can terminate the agreement by written notice. Any sales will be made under Surrozen’s existing Form S-3 shelf registration, using a base prospectus and an August 29, 2025 prospectus supplement.
Surrozen, Inc. discloses a high-risk development-stage profile: the company has a history of operating losses and expects to continue incurring significant losses while none of its product candidates have regulatory approval. The filing emphasizes substantial funding needs to advance its Wnt therapeutics pipeline and acknowledges that future equity or debt financings could dilute existing shareholders. It lists multiple outstanding and reserved equity instruments, including 8,499,821 shares (or pre-funded warrants) offered at $11.60 per share in a March 2025 private placement and several classes of warrants and options exercisable at specified prices.
The company also details material operational risks: reliance on third parties for trials and manufacturing, potential clinical delays or safety setbacks, competitive pressures, international regulatory and trade risks, and concentrated stockholder voting control that may limit minority influence.
Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 455,299 shares of Surrozen, Inc. common stock (CUSIP 86889P208), representing 5.18% of the outstanding class as of June 30, 2025. The reported total includes 225,772 shares that may be acquired within 60 days upon exercise of warrants. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross jointly report beneficial ownership of 1,016,197 shares of Surrozen common stock, representing 11.4% of the class. That total comprises 686,539 currently outstanding shares and 329,658 shares issuable upon exercise of warrants. The Reporting Persons disclose no sole voting or dispositive power; they report shared voting power of 963,133 and shared dispositive power of 1,016,197.
The 11.4% figure is calculated using a base of 8,562,584 shares outstanding plus certain warrants added pursuant to Rule 13d-3(d)(1)(i), including Series E Warrants and 2024 PIPE Series A and B warrants. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.